Research Projects

This research explores a promising new approach to treating vitiligo, a skin condition where the immune system mistakenly attacks pigment-producing cells, causing white patches. Current treatments often require daily use, are ineffective for some, and symptoms can return quickly after stopping therapy. The study focuses on short-chain fatty acids (SCFAs), natural compounds produced by gut bacteria that reduce inflammation and support healthy immune function. Recent findings suggest vitiligo patients may have lower SCFA levels, potentially worsening the condition by triggering harmful immune responses. The project will measure SCFA levels in blood and skin samples from vitiligo patients compared to healthy individuals to confirm this link. Using human skin incorporating immune cells, fibroblasts, keratinocytes, and melanocytes, the study will model vitiligo’s immune-mediated pathology in vitro as well as in vivo and test SCFA treatments for their ability to block inflammatory signals, reduce harmful immune cell activity, protect melanocytes, and promote skin repigmentation. In mice with vitiligo-like symptoms, SCFA treatment will be evaluated to assess its ability to slow or stop the spread of white patches and encourage repigmentation. By linking gut health to skin immunity, this work aims to develop a sustainable treatment strategy targeting vitiligo’s root causes, potentially leading to therapies that are easier to use, longer-lasting, and more effective, improving the quality of life for those affected.